

Real Time Estimates & Accurate Forecasts
The Global Longevity and Anti-Senescence Therapy market is expected to reach around $800 million by 2026, with a projected CAGR of 13.9% during the forecast period.
The Global Longevity and Anti-Senescence Therapy market is expected to reach around $800 million by 2026, with a projected CAGR of 13.9% during the forecast period. The term “longevity” is sometimes used as an alternative word for “life expectancy” in demography. However, the term longevity is every so often meant to refer only to particularly long-lived members of a population, whereas life expectancy is always described statistically as the average number of years outstanding at a given age. Further, anti-senescence is the process by which cells stop dividing irreversibly and enter a state of permanent growth arrest, eliminating cell death.
Rising base of geriatric population across the globe, and growing awareness of anti-aging products among generation X, Y, and later generations are the major factors driving the growth of the global longevity and anti-senescence therapy market. In addition, surging level of disposable income and increasing advancements in anti-senescence technologies are also gaining traction in the global market. Moreover, increasing prominence on stem cell research and surging demand for cell-based assays in research and development is likely to gain significant impetus for the Longevity and Anti-Senescence Therapy market share in the forthcoming years.
The study provides a crucial view of longevity and anti-senescence therapy by segmenting the market based on therapy, application, and geography. The Therapy segment includes senolytic drug therapy, gene therapy, immunotherapy, and others. On the basis of application, the segment can be bifurcated into longevity, senescence inhibition, cardiovascular diseases, neural degenerative diseases, ophthalmology disorders, and others. Furthermore, geographical coverage has been offered for each of the major regions including North America, Asia-Pacific, Europe, Row, and South America.
By Therapy
By Application
By Geography
TABLE OF CONTENTS
Chapter 1 Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Market Scope
Chapter 2 Research Methodology
2.1 Primary Research
2.2 Research Methodology
2.3 Assumptions & Exclusions
2.4 Secondary Data Therapys
Chapter 3 Market Overview
3.1 Report Segmentation & Scope
3.2 Key Market Trends
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunities
3.3 Porter’s Five Forces Analysis
3.4 Market Share Analysis
Chapter 4 Global Longevity and Anti-Senescence Therapy Market by Therapy: Market Size and Forecast, 2018 – 2026
4.1 Introduction
4.1.1 Market Size and Forecast
4.2 Senolytic Drug Therapy
4.2.1 Market Size and Forecast
4.3 Gene Therapy
4.3.1 Market Size and Forecast
4.4 Immunotherapy
4.4.1 Market Size and Forecast
4.5 Others
4.5.1 Market Size and Forecast
Chapter 5 Global Longevity and Anti-Senescence Therapy Market by End-User Industry: Market Size and Forecast, 2018 – 2026
5.1 Introduction
5.1.1 Market Size and Forecast
5.2 Longevity
5.2.1 Market Size and Forecast
5.3 Senescence Inhibition
5.3.1 Market Size and Forecast
5.4 Cardiovascular Diseases
5.4.1 Market Size and Forecast
5.5 Neural Degenerative Diseases
5.5.1 Market Size and Forecast
5.6 Ophthalmology Disorders
5.6.1 Market Size and Forecast
5.7 Others
5.7.1 Market Size and Forecast
Chapter 6 Global Longevity and Anti-Senescence Therapy Market by Geography: Market Size and Forecast, 2018 – 2026
6.1 Introduction
6.1.1 Market Size and Forecast
6.2 North America
6.2.1 North America Market Size & Forecast, By Country
6.2.2 North America Market Size & Forecast, By Therapy
6.2.3 North America Market Size & Forecast, By End-User Industry
6.2.4 The U.S.
6.2.4.1 Market Size and Forecast
6.2.5 Canada
6.2.5.1 Market Size and Forecast
6.2.6 Mexico
6.2.6.1 Market Size and Forecast
6.3 Europe
6.3.1 Europe Market Size and Forecast, By Country
6.3.2 Europe Market Size and Forecast, By Therapy
6.3.3 Europe Market Size & Forecast, By End-User Industry
6.3.4 UK
6.3.4.1 Market Size and Forecast
6.3.5 Germany
6.3.5.1 Market Size and Forecast
6.3.6 France
6.3.6.1 Market Size and Forecast
6.3.7 Italy
6.3.7.1 Market Size and Forecast
6.3.8 Spain
6.3.8.1 Market Size and Forecast
6.3.9 Rest of Europe
6.3.9.1 Market Size and Forecast
6.4 Asia-Pacific
6.4.1 Asia-Pacific Market Size and Forecast, By Country
6.4.2 Asia-Pacific Market Size and Forecast, By Therapy
6.4.3 Asia-Pacific Market Size and Forecast, By End-User Industry
6.4.4 India
6.4.4.1 Market Size and Forecast
6.4.5 China
6.4.5.1 Market Size and Forecast
6.4.6 Australia
6.4.6.1 Market Size and Forecast
6.4.7 Japan
6.4.7.1 Market Size and Forecast
6.4.8 South Korea
6.4.8.1 Market Size and Forecast
6.4.9 Rest of Asia-Pacific
6.4.9.1 Market Size and Forecast
6.5 South America
6.5.1 South America Market Size and Forecast, By Country
6.5.2 South America Market Size and Forecast, By Therapy
6.5.3 South America Market Size and Forecast, By End-User Industry
6.5.4 Brazil
6.5.4.1 Market Size and Forecast
6.5.5 Rest of South America
6.5.5.1 Market Size and Forecast
6.6 RoW
6.6.1 RoW Market Size and Forecast, By Country
6.6.2 RoW Market Size and Forecast, By Therapy
6.6.3 RoW Market Size and Forecast, By End-User Industry
6.6.4 Middle East
6.6.4.1 Market Size and Forecast
6.6.5 Africa
6.6.5.1 Market Size and Forecast
Chapter 7 Company Profiles
7.1 Unity Biotechnology
7.2 Acorda Therapeutics
7.3 Calico Life Sciences
7.4 Agex Therapeutics
7.5 Celgene
7.6 Human Longevity Inc.
7.7 Cleara Biotech
7.8 Powervision Inc.
7.9 Cohbar
7.10 Insilico Medicine
7.11 Oisin Biotechnology
7.12 Prana Biotechnology Ltd.
7.13 Recursion Pharmaceuticals
7.14 Sierra Sciences LLC
7.15 Proteostasis Therapeutics Inc.
7.16 Senex Biotechnology
7.17 Senolytic Therapeutics
7.18 T.A. Sciences
Longevity and Anti-Senescence Therapy Market Key Players